US heart institute considers exclusive license for catheter heart-ablation patents to AntaraCore
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, is considering giving AntaraCore, Systems, Inc., a Dover, Delaware company, an exclusive license to use a set of patent applications. The patents cover a catheter-based method that treats dangerous heart rhythm problems in humans by ablating, or destroying, a small area of heart muscle from inside the heart. The notice is only a proposal at this stage.
This summary was generated by AI; the official source prevails.
What does it mean?
A government heart research body is thinking about letting one company be the only one allowed to use its patented heart treatment method. This is a proposal, not a final deal.
Who is affected?
AntaraCore, Systems, Inc. and other companies that might want to make or sell a similar catheter treatment for irregular heartbeats.